Herantis Pharma Oyj

€1.12As of Sun 8 Nov 2026, 12:00 UTC
HEL:HRTISHealthcare
Country Finland
PE (Fwd) •••
TSR 10Y CAGR (2.07%)
Div yield —
ROE (1415.14%)
Biotechnology
Beta (5Y) 0.58
PE TTM —
TSR TTM (50.31%)
Mkt cap €29.63M
ROIC (814.59%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
€1.20
7.29%
(8.88%)
Buy 12|4|7|5|0
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.03
0.03
0.03
0.03
28.06%
19.87%
11.85%
5.36%
Revenue€M
2.046
1.986
2.048
2.109
1.33%
(6.66%)
(2.45%)
2.85%
Peers (US$33.27M)
Cap (US$)
PE
162.4M
—
Capital
TTM
5Y
10Y
Leveragex
0.244
(0.353)
(0.286)
EBIT/Intx
0.904
0.448
0.446
Own earn%
(80.63)
144.90
139.34
Sh yield%
48.66
50.87
50.94
Owners
Insiders/Inst%
12.52
64.90
Short interest%
0.83
SBC / revenue%
1.90
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
22–28
$1 testx
0.1
Incr. ROIC%
11